Start here if you're new
what it is
Milestone develops a nasal spray for sudden fast-heart episodes.
how it gets paid
Last year Milestone Pharma made $1M in revenue. CARDAMYST U.S. launch was the main engine at $0M, or 40% of sales.
what just happened
Milestone posted -$0.60 EPS while revenue sat at $0M.
At a glance
C++ balance sheet — some cracks in the foundation
55/100 earnings predictability — expect surprises
-$0.67 fy2024 eps est
$1M fy2023 rev est
1.5 beta
xvary composite: 33/100 — weak
What they do
Milestone develops a nasal spray for sudden fast-heart episodes.
CARDAMYST is portable, so it beats the ER-first routine. Milestone says it is now in U.S. retail pharmacies, and the company has 33 employees, so you are buying a tiny team behind one product. That is the whole point and the whole risk.
How they make money
$1M
annual revenue
CARDAMYST U.S. launch
$0M
+0.0%
PSVT development
$0M
0.0%
AFib-RVR development
$0M
0.0%
Corporate / other
$0M
0.0%
The products that matter
lead PSVT nasal spray
CARDAMYST (etripamil nasal spray)
January 2026 commercial availability
this is the whole equity story. the company describes it as its only asset, and today's revenue base is still only about $1M.
core asset
current revenue bucket
Collaboration & Other
$1M · 100% of current revenue
this is what the business reports today, which tells you commercialization has not yet shown up in a meaningful way.
current revenue
funding the wait
Cash and balance sheet
$82.58M cash · $57M debt
it is not a product, but it matters as much as one. this balance sheet is what gives management time to prove launch demand.
runway
Key numbers
$145M
market cap
You are paying a tiny public price for a drug company with one launch. That leaves very little room for disappointment.
$57M
long-term debt
The debt is 39% of the market cap, so financing pressure is not a side quest.
33
employees
A 33-person shop has no room for sloppy execution.
$0.67
FY2024 EPS est
still had losses at 67 cents a share, so profitability is not here yet.
Financial health
C++
strength
- balance sheet grade C++ — below average — limited financial resources
- risk rank 5 — safer than 5% of stocks
- price stability 5 / 100
- long-term debt $57M (28% of capital)
C++ — below average. watch for debt servicing and cash burn.
Total return vs. market
Return history isn't available for MIST right now.
source: institutional data · return history unavailable
What just happened
missed estimates
Milestone posted -$0.60 EPS while revenue sat at $0M.
That lines up with a pre-commercial company. Yahoo shows trailing revenue down 75.51% vs. prior year, and still had FY2024 EPS at -$0.67.
$0M
revenue
$0.60
eps
75.51%
revenue vs. last year
cash burn
The -$0.60 EPS loss matters because revenue is still $0M, so every quarter is burn before scale.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the biggest risk is not abstract biotech uncertainty. it is one launch, one balance sheet, and almost no existing revenue cushion.
med
commercial uptake for CARDAMYST disappoints
January 2026 availability is not the same thing as adoption. With roughly $1M of revenue today, there is no established sales base to hide weak early demand.
if revenue still looks close to today's level after launch is supposed to be underway, the valuation stops being about upside and starts being about what went wrong.
med
cash burn outruns the launch timeline
$82.58M of cash sounds decent until you pair it with a n/a operating margin and $57M of long-term debt. This business does not have the luxury of a slow commercial ramp.
if launch takes longer than investors expect, financing risk moves to center stage and existing shareholders feel it first.
med
single-asset concentration leaves no backup plan
Management already tells you the story: CARDAMYST is the asset that matters. That is focus, but it is also concentration. There is no diversified product portfolio here.
one product issue can hit sentiment, valuation, and balance-sheet flexibility at the same time.
With a ~$145M market cap, about $1M of revenue, and one commercial asset, you do not need multiple things to go wrong here. One is enough.
source: institutional data · regulatory filings · risk analysis
Pay attention to
calendar
January 2026 commercial availability
That is the date the story has to start leaving the lab and entering the income statement. For MIST, the calendar is a thesis input.
metric
revenue above the current ~$1M base
If sales do not begin to move materially above today's starting point, you are still owning a concept stock with a product attached.
risk
cash versus debt
Keep $82.58M of cash next to $57M of debt in your head at all times. The launch does not get unlimited time to work.
trend
volatility staying high
A 1.5 beta and 5 / 100 price stability say sentiment can move faster than fundamentals. Expect air pockets, not straight lines.
Analyst rankings
short-term outlook
thin coverage
analyst target data is thin here. in human-speak, there is no broad wall street consensus carrying this stock.
risk profile
volatile
small-cap biotech with one core asset. You should expect wider swings than you would get from a diversified drug company.
chart momentum
catalyst-led
this chart is mostly a scoreboard for product news, launch progress, and financing nerves. Technicals matter, but the headlines matter more.
earnings predictability
55/100
that score says the numbers can shift because the business model itself is still shifting from development to commercialization.
source: institutional data
Institutional activity
institutional ownership data for MIST is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$2
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive